FPX 01

Drug Profile

FPX 01

Alternative Names: FPX01

Latest Information Update: 23 Sep 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Centre for Probe Development and Commercialization
  • Class Radiopharmaceuticals
  • Mechanism of Action Ionising radiation emitters
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I Cancer

Most Recent Events

  • 25 Sep 2017 Fusion Pharmaceuticals plans clinical development in 2018
  • 23 Sep 2016 Fusion Pharmaceuticals plans to apply for breakthrough therapy designation for FPX 01 in USA (Fusion Pharmaceuticals pipeline, September 2016)
  • 23 Sep 2016 Fusion Pharmaceuticals announces intention to commercialise FPX 01 in 2019 (Fusion Pharmaceuticals pipeline, September 2016)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top